| | Title | Author(s) | Year | View Count | | 1 |  | Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population | Fung, J; Lai, CL; Yuen, JCH; Wong, DKH; Tanaka, Y; Mizokami, M; Yuen, MF | 2007 | 94 |
| 2 | | Etiologies of chronic liver diseases in Hong Kong | Fung, KTT; Fung, J; Lai, CL; Yuen, MF | 2007 | 89 |
| 3 |  | Difference in T Helper Responses During Hepatitis Flares in HBeAg-positive Patients with Genotypes B and C: Implication for Early HBeAg Seroconversion | Yuen, RMF; Wong, DKH; Zheng, B; Chan, CCS; Yuen, JCH; Wong, BCY; Lai, CL | 2007 | 277 |
| 4 | | Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B | Yuan, HJ; KaHo Wong, D; Doutreloigne, J; Sablon, E; Lai, CL; Yuen, MF | 2007 | 275 |
| 5 | | Evolution of Primary and Compensatory Lamivudine-Resistance Mutations during Long-term Lamivudine Treatment in Chronic HBV-Infected Patients Assessed by a Line Probe Assay. | Libbrecht, E; Doutreloigne, J; Van de Velde, H; Yuen, RMF; Lai, CL | 2007 | 70 |
| 6 | | HBV genotypes: implications for treatment and management. | Yuen, RMF; Lai, CL | 2007 | 71 |
| 7 | | The natural history and treatment of CHB: critical evaluation of treatment criteria and endpoints | Lai, CL; Yuen, RMF | 2007 | 73 |
| 8 |  | Telbivudine versus lamivudine in patients with chronic hepatitis B | Lai, CL; Gane, E; Liaw, YF; Hsu, CW; Thongsawat, S; Wang, Y; Chen, Y; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, NV; Di Bisceglie, AM; Zeuzem, S; Moon, YM; Goodman, Z; Chao, G; Constance, BF; Brown, NA | 2007 | 245 |
| 9 | | The natural history and treatment of chronic hepatitis B: A critical evaluation of standard treatment criteria and end points | Lai, CL; Yuen, MF | 2007 | 43 |
| 10 | | Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay | Libbrecht, E; Doutreloigne, J; Van De Velde, H; Yuen, MF; Lai, CL; Shapiro, F; Sablon, E | 2007 | 56 |
| 11 | | Hepatitis B virus genotypes: natural history and implications for treatment. | Yuen, MF; Lai, CL | 2007 | 50 |
| 12 | | Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease | Yuen, MF; Seto, WK; Chow, DHF; Tsui, K; Wong, DKH; Ngai, VWS; Wong, BCY; Fung, J; Yuen, JCH; Lai, CL | 2007 | 290 |
| 13 | | Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection | Wong, DKH; Tanaka, Y; Lai, CL; Mizokami, M; Fung, J; Yuen, MF | 2007 | 56 |
| 14 | | A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B | Yuen, MF; Kim, J; Kim, CR; Ngai, V; Yuen, JCH; Min, C; Kang, HM; Shin, BS; Yoo, SD; Lai, CL | 2006 | 202 |
| 15 | | Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma | Tanaka, Y; Mukaide, M; Orito, E; Yuen, MF; Ito, K; Kurbanov, F; Sugauchi, F; Asahina, Y; Izumi, N; Kato, M; Lai, CL; Ueda, R; Mizokami, M | 2006 | 100 |
| 16 | | A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C | Orito, E; Fujiwara, K; Tanaka, Y; Yuen, MF; Lai, CL; Kato, T; Sugauchi, F; Kusakabe, A; Sata, M; Okanoue, T; Niitsuma, H; Sakugawa, H; Hasegawa, I; Mizokami, M | 2006 | 106 |
| 17 | | Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality | Tanaka, Y; Kurbanov, F; Mano, S; Orito, E; Vargas, V; Esteban, JI; Yuen, M; Lai, C; Kramvis, A; Kew, MC; Smuts, HE; Netesov, SV; Alter, HJ; Mizokami, M | 2006 | 112 |
| 18 | | Recommendations and potential future options in the treatment of hepatitis B | Yuen, MF; Lai, CL | 2006 | 83 |
| 19 | | Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: Pharmacodynamic implications | Zhou, XJ; Lim, SG; Lloyd, DM; Chao, GC; Brown, NA; Lai, CL | 2006 | 237 |
| 20 | | Do baseline ALT levels predict complications of chronic hepatitis B?: authors' reply | Yuen, MF; Lai, CL | 2006 | 216 |
|
